research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
Search
for
Sort by
Research
330-360 / 1000+ results 
research Topical 2% Tofacitinib for Children with Alopecia Areata, Alopecia Totalis, and Alopecia Universalis
Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.
research Experience with Oral Tofacitinib in 8 Adolescent Patients with Alopecia Universalis
Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
research Pericardial Disorders During Open-Label Study of 1,869 Severely Hypertensive Patients Treated with Minoxidil
Minoxidil doesn't increase pericardial disorder risk, but may cause fluid accumulation.
research Tofacitinib 2% Ointment, a Topical Janus Kinase Inhibitor, for the Treatment of Alopecia Areata: A Pilot Study of 10 Patients
Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
research Alefacept for Severe Alopecia Areata: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial
Alefacept does not effectively treat severe alopecia areata.
research A Randomized Placebo-Controlled Single-Center Pilot Study of the Safety and Efficacy of Apremilast in Subjects with Moderate-to-Severe Alopecia Areata
Apremilast was not effective in treating moderate-to-severe alopecia areata.
research Objective Outcome Measures: Collecting Meaningful Data on Alopecia Areata
The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.
research Topical Calcipotriol Therapy for Mild-to-Moderate Alopecia Areata: A Retrospective Study
Calcipotriol cream can effectively and safely treat mild-to-moderate patchy hair loss.
research Ritlecitinib And Brepocitinib Demonstrate Significant Improvement In Scalp Alopecia Areata Biomarkers
Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
research Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents
Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
research Serum Vitamin D Level Is Related to Disease Severity in Pediatric Alopecia Areata
Low vitamin D can worsen pediatric alopecia areata.
research Treatment of Alopecia Areata in Pre-Adolescent Children with Oral Tofacitinib: A Retrospective Study
Oral tofacitinib may effectively treat hair loss in children with alopecia areata.
research Quality of Life in Patients with Alopecia Areata: A Hospital-Based Cross-Sectional Study
Alopecia areata significantly lowers quality of life, especially in personal and social areas, and more so if the patient is also depressed.
research Bilateral Half-Head Comparison of 1% Anthralin Ointment in Children with Alopecia Areata
1% anthralin ointment is effective and safe for treating severe alopecia areata in children.
research Binding Interactions of Keratin-Based Hair Fiber Extract to Gold, Keratin, and BMP-2
Keratin from hair binds well to gold and BMP-2, useful for bone repair.
research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials
Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
research Dupilumab Therapy for Alopecia Areata in Pediatric Patients with Concomitant Atopic Dermatitis
Dupilumab may help children with alopecia areata and atopic dermatitis regrow hair.
research Efficacy of Postbiotics in a PRP-Like Cosmetic Product for the Treatment of Alopecia Areata: A Randomized Double-Blinded Parallel-Group Study
The PRP-like cosmetic product with postbiotics effectively treats hair loss in Alopecia areata.
research Clinical Experiences on Alopecia Areata Treatment with Tofacitinib: A Study of 63 Patients
Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
research Insights Learned from L457(3.43)R, an Activating Mutant of the Human Lutropin Receptor
The L457(3.43)R mutation in the human lutropin receptor causes increased activity and hormone insensitivity, leading to precocious puberty.
research Role of Hair Prostheses (Wigs) in Patients with Severe Alopecia Areata
Wigs significantly improve the well-being of people with severe hair loss.
research Extensive Alopecia Areata: Not Necessarily Recalcitrant to Therapy
Some people with severe, long-lasting baldness responded well to a specific combination treatment.
research The Application of Radiochemical Techniques to the Study of the Interaction of Hair Fibers with Aqueous Solutions
Hair absorbs different substances from solutions based on pH levels.
research The In Vitro Assembly of Hair Follicle Keratins: Comparison of Cortex and Companion Layer Keratins
Different conditions affect how hair proteins assemble, and certain mutations can change their structure.
research Janus Kinase Inhibitors For Alopecia Areata
JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.
research Trichoscopy as an Evaluation Method for Alopecia Areata Treatment: A Comparative Study
Trichoscopy is useful for diagnosing and monitoring alopecia areata treatment.
research Assessment of Vitamin D Level in Patients with Alopecia Areata
Low vitamin D levels are common in people with Alopecia Areata.
research Successful Treatment of Resistant Alopecia Areata with a Phototoxic Dose of Ultraviolet A After Topical 8-Methoxypsoralen Application
This therapy effectively treats resistant alopecia areata with minimal side effects.
research Clearance of Ichthyosis Linearis Circumflexa with Balneophototherapy
Balneophototherapy effectively treats ichthyosis linearis circumflexa but may need ongoing treatment due to short remission.